Perspective Therapeutics, Inc.CATXEarnings & Financial Report
NYSE · Health Care · Pharmaceutical Preparations
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals.
CATX Q4 FY2023 Key Financial Metrics
Revenue
$-3.8M
Gross Profit
N/A
Operating Profit
$-11.7M
Net Profit
N/A
Gross Margin
N/A
Operating Margin
306.9%
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.97
Perspective Therapeutics, Inc. Q4 FY2023 Financial Summary
Perspective Therapeutics, Inc. reported revenue of $-3.8M for Q4 FY2023, with a net profit of N/A (N/A margin).
Key Financial Metrics
| Total Revenue | $-3.8M |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | 306.9% |
| Report Period | Q4 FY2023 |
Perspective Therapeutics, Inc. Quarterly Revenue & Net Profit History
Perspective Therapeutics, Inc. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2023 | $-3.8M | — | N/A | N/A |
| Q3 FY2022 | $1.7M | -33.0% | $-4.1M | -236.9% |
| Q1 FY2022 | $2.9M | +11.9% | $-1.3M | -46.3% |
Income Statement
| Q1 2022 | Q3 2022 | Q4 2023 | |
|---|---|---|---|
| Revenue | $2.9M | $1.7M | $-3.8M |
| YoY Growth | 11.9% | -33.0% | N/A |
Balance Sheet
| Q1 2022 | Q3 2022 | Q4 2023 | |
|---|---|---|---|
| Assets | $66.1M | $62.5M | $97.9M |
| Liabilities | $2.9M | $4.8M | $22.7M |
| Equity | $63.2M | $57.7M | $75.2M |
Cash Flow
| Q1 2022 | Q3 2022 | Q4 2023 | |
|---|---|---|---|
| Operating CF | $-1.4M | $-1.8M | $-9.0M |